Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Cefpodoxime Formulations in Acute Sinusitis
NCT03729258Phase 3Unknown
- Sponsor
- Neutec Group
- Start
- May 2019
- Primary completion
- Oct 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cefpodoxime in Acute bacterial rhinosinusitis (ABRS), sponsored by Neutec Group. Status: unknown.
02
Drugs
cefpodoxime
03
Conditions
Acute bacterial rhinosinusitis (ABRS)
Beyond the preview
Go deeper on NCT03729258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729258.